GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynCore Biotechnology Co Ltd (ROCO:4192) » Definitions » Cyclically Adjusted Revenue per Share

SynCore Biotechnology Co (ROCO:4192) Cyclically Adjusted Revenue per Share : NT$0.60 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is SynCore Biotechnology Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

SynCore Biotechnology Co's adjusted revenue per share for the three months ended in Mar. 2024 was NT$0.124. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$0.60 for the trailing ten years ended in Mar. 2024.

During the past 12 months, SynCore Biotechnology Co's average Cyclically Adjusted Revenue Growth Rate was 7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-23), SynCore Biotechnology Co's current stock price is NT$44.40. SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was NT$0.60. SynCore Biotechnology Co's Cyclically Adjusted PS Ratio of today is 74.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SynCore Biotechnology Co was 176.87. The lowest was 61.29. And the median was 83.42.


SynCore Biotechnology Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynCore Biotechnology Co Cyclically Adjusted Revenue per Share Chart

SynCore Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.55 0.59

SynCore Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.57 0.58 0.59 0.60

Competitive Comparison of SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, SynCore Biotechnology Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynCore Biotechnology Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynCore Biotechnology Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SynCore Biotechnology Co's Cyclically Adjusted PS Ratio falls into.



SynCore Biotechnology Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SynCore Biotechnology Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.124/131.7762*131.7762
=0.124

Current CPI (Mar. 2024) = 131.7762.

SynCore Biotechnology Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.086 100.560 0.113
201409 0.092 100.428 0.121
201412 0.095 99.070 0.126
201503 0.082 99.621 0.108
201506 0.666 100.684 0.872
201509 0.112 100.392 0.147
201512 0.114 99.792 0.151
201603 0.093 100.470 0.122
201606 0.113 101.688 0.146
201609 0.100 101.861 0.129
201612 0.106 101.863 0.137
201703 0.097 102.862 0.124
201706 0.120 103.349 0.153
201709 0.108 104.136 0.137
201712 0.105 104.011 0.133
201803 0.096 105.290 0.120
201806 0.103 106.317 0.128
201809 0.093 106.507 0.115
201812 0.085 105.998 0.106
201903 0.286 107.251 0.351
201906 0.103 108.070 0.126
201909 0.083 108.329 0.101
201912 0.080 108.420 0.097
202003 0.079 108.902 0.096
202006 0.060 108.767 0.073
202009 0.136 109.815 0.163
202012 0.196 109.897 0.235
202103 0.044 111.754 0.052
202106 0.041 114.631 0.047
202109 0.047 115.734 0.054
202112 0.092 117.630 0.103
202203 0.108 121.301 0.117
202206 0.093 125.017 0.098
202209 0.144 125.227 0.152
202212 0.163 125.222 0.172
202303 0.120 127.348 0.124
202306 0.145 128.729 0.148
202309 0.186 129.860 0.189
202312 0.176 129.419 0.179
202403 0.124 131.776 0.124

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


SynCore Biotechnology Co  (ROCO:4192) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

SynCore Biotechnology Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=44.40/0.6
=74.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SynCore Biotechnology Co was 176.87. The lowest was 61.29. And the median was 83.42.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


SynCore Biotechnology Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of SynCore Biotechnology Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


SynCore Biotechnology Co (ROCO:4192) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269
SynCore Biotechnology Co Ltd is a biopharmaceutical company. Its pipeline products concentrate on the ophthalmology, oncology, and dermatology fields. The pipeline products of the company include SB01 and 02, SB03, SB04, and SB05. It is engaged in drug development and sale, food advisory, medicine inspection, biotechnology service and intellectual property. It operates in a single industry, the new drug development.

SynCore Biotechnology Co (ROCO:4192) Headlines

No Headlines